RENE GONZALEZ to Proto-Oncogene Proteins B-raf
This is a "connection" page, showing publications RENE GONZALEZ has written about Proto-Oncogene Proteins B-raf.
Connection Strength
2.192
-
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol. 2014 Nov 20; 32(33):3697-704.
Score: 0.407
-
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers. Cancer. 2024 May 15; 130(10):1784-1796.
Score: 0.194
-
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clin Cancer Res. 2020 01 01; 26(1):46-53.
Score: 0.145
-
Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
Score: 0.144
-
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat Med. 2019 06; 25(6):929-935.
Score: 0.140
-
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. J Clin Oncol. 2018 03 01; 36(7):667-673.
Score: 0.125
-
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma. Nucl Med Commun. 2016 Feb; 37(2):122-8.
Score: 0.111
-
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016 Mar 10; 34(8):871-8.
Score: 0.111
-
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol. 2014 Aug; 15(9):954-65.
Score: 0.100
-
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
Score: 0.092
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
Score: 0.090
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 11 01; 367(18):1694-703.
Score: 0.088
-
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012 Feb 23; 366(8):707-14.
Score: 0.085
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med. 2012 Jan 19; 366(3):207-15.
Score: 0.084
-
Novel therapies in melanoma. Immunotherapy. 2011 Dec; 3(12):1461-9.
Score: 0.083
-
Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun. 2020 10 16; 11(1):5259.
Score: 0.039
-
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 10 17; 381(16):1535-1546.
Score: 0.036
-
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 11; 19(11):1480-1492.
Score: 0.034
-
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res. 2017 12; 27(6):585-590.
Score: 0.032
-
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer. 2017 11; 86:37-45.
Score: 0.031
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
Score: 0.022